Drugs / MAVELERTINIB
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02349633 | May 2015 → May 2020 | non-small cell lung carcinoma | Pfizer | Terminated | No outcome recorded Stop: Business |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MAVELERTINIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989970 ↗ |
| Known as | Egfr t790m inhibitor pf-06747775 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989970 ↗ |
| Known as | PF-06747775 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02349633 ↗ |
| Action | Inhibit | “EPIDERMAL GROWTH FACTOR RECEPTOR T790M INHIBITOR” NCT02349633 ↗1“Epidermal growth factor receptor erbB1 inhibitor” CHEMBL3989970 ↗ |
| Modality | Small molecule | — CHEMBL3989970 ↗ |
| Route | Oral | “PF-06747775 200 mg by mouth (PO) daily (QD)” NCT02349633 ↗ |
| Target | EGFR | “Epidermal growth factor receptor erbB1 inhibitor” CHEMBL3989970 ↗ |